RMTG · Regenerative Medical Technology Group Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of approximately $79,484,265 and a working capital deficit of $40,328,417 as of June 30, 2026, and future losses are anticipated. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 19, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $9.41M | $5.1M | $4.11M | $2.41M | $1.53M | $437.89K | $55.08K | $30.1K | $50.12K | $29.24K | |
| $3.79M | $2.29M | $1.28M | $734.29K | $653.26K | $287.75K | $43.95K | $55.52K | $68.33K | $4810 | |
| $5.63M | $2.81M | $2.82M | $1.68M | $876.97K | $150.14K | $11.13K | -$25.42K | -$18.22K | $24.43K | |
| — | 55.11% | 68.73% | 69.53% | 57.31% | 34.29% | 20.2% | -84.45% | -36.35% | 83.55% | |
| $1.76M | $1.12M | $798.32K | $752.53K | $424.26K | $149.37K | $29.87K | $31.36K | $43.06K | $91.98K | |
| — | — | — | — | $8.2M | — | — | — | — | — | |
| $97.54K | $97.54K | $97.54K | $97.54K | — | — | — | — | — | — | |
| $362.93K | $281.07K | $220.56K | $310.1K | $152.74K | $40.86K | $800 | $800 | $200 | — | |
| $5.58M | $3.68M | $2.74M | $2.39M | $2.06M | $10.07M | $459.55K | $1.57M | $236.98K | $525.07K | |
| $43.73K | -$867.16K | $81.18K | -$715.23K | — | — | — | — | — | — | |
| — | -17% | 1.98% | -29.68% | — | — | — | — | — | — | |
| $406.65K | -$586.1K | $301.74K | -$405.12K | — | — | — | — | — | — | |
| $9.92M | $7.45M | $5.64M | $6.49M | — | $2.72M | $4.2M | $570.99K | $528.4K | $383.66K | |
| -$9.43M | -$6.95M | -$5.64M | -$9.1M | -$4.4M | -$2.72M | — | — | — | $2226 | |
| — | -$1.64M | -$1.16M | -$2.06M | -$1.16M | -$2.71M | — | — | — | — | |
| -$9.39M | -$7.81M | -$5.56M | -$9.81M | -$5.51M | -$12.88M | -$5.9M | -$2.51M | -$2.06M | -$377.01K | |
| — | -153.18% | -135.43% | -407.21% | -359.87% | -2942.42% | -10703.47% | -8335.2% | -4105.61% | -1289.31% | |
| USD/shares | -$0.73 | -$0.62 | -$0.44 | -$0.79 | -$0.45 | -$1.12 | -$0.63 | -$0.47 | -$0.50 | — |
| USD/shares | -$0.73 | -$0.62 | -$0.44 | -$0.79 | -$0.45 | -$1.12 | — | — | — | — |
| shares | — | 12.63M | 12.53M | 12.45M | 12.22M | 11.48M | 9.34M | 5.31M | 4.09M | 3.47M |
| shares | — | 12.63M | 12.53M | 12.45M | 12.22M | 11.48M | — | — | 4.09M | 3.47M |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Notes payable, including current maturities | 2026-06-30 | USD 17,684,889 | 10-Q filed 2026-08-19 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Operating lease liabilities | 2026-06-30 | USD 650,106 | 10-Q filed 2026-08-19 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 67 similar-size Biotechnology companies (of 559 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Product Supplies | $2,024,573 | $1,748,961 | $1,329,159 | $866,104 | $209,706 |
| Patient Procedures | $1,874,386 | $1,371,654 | $318,999 | $221,255 | — |
| Training | $1,125,521 | $809,654 | $599,425 | $279,404 | $112,970 |
| Equipments | $75,835 | $177,225 | $162,370 | $163,460 | $115,211 |